GlassScriptPhysician profile
Cici Liu
NPI 1952620577
$7,331.59
in general payments reported to CMS, 2019-2025
25 companies · $4,551 in 2025
The $4,551 reported for 2025 was more than what 85% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2023: $593 · 2024: $2,086 · 2025: $4,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791 · Education: $2,500 · Travel and Lodging: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.72 |
| Education | $2,500.00 |
| Travel and Lodging | $1,938.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,903.38 | 2023-2025 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $1,331.71 | 2024 | Enseal |
| Astrazeneca Pharmaceuticals LP | $442.20 | 2023-2025 | Lynparza |
| Myriad Genetic Laboratories, INC. | $205.78 | 2023-2024 | Precisetumor, Mychoice Cdx, Myrisk |
| Conmed Corporation | $168.44 | 2023-2024 | Airseal |
| Ethicon US, LLC | $165.65 | 2023-2025 | Harmonic, Stratafix, Proximate |
| Eisai INC. | $149.56 | 2024-2025 | |
| Dilon Technologies, INC. | $147.65 | 2024 | Hemoblast Bellows |
| Genentech USA, INC. | $102.26 | 2019 | |
| Sumitomo Pharma America, INC. | $97.96 | 2025 | Myfembree, Gemtesa |
| Smith+Nephew, INC. | $95.89 | 2025 | Stravix |
| Bluewind Medical | $81.74 | 2025 | Revi |
| Astellas Pharma US INC | $64.18 | 2025 | Veozah |
| Baxter Healthcare | $58.68 | 2024-2025 | Floseal, Perclot |
| Merck Sharp & Dohme LLC | $44.55 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $41.48 | 2023-2025 | |
| Minerva Surgical, INC | $35.72 | 2025 | |
| Hologic Sales and Service, LLC | $34.65 | 2025 | Acessa Provu System |
| Abbvie INC. | $32.04 | 2025 | |
| Coloplast Corp | $29.31 | 2024-2025 | |
| Medtronic, INC. | $23.01 | 2023 | Interstim |
| Seagen INC. | $22.55 | 2023 | Tivdak |
| Tempus Ai, INC | $19.48 | 2025 | Xt Cdx |
| Heron Therapeutics, INC. | $19.18 | 2023 | Zynrelef |
| Agile Therapeutics, INC. | $14.54 | 2024 | Twirla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cici Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.